| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1997;113:194-201
© 1997 Mosby, Inc.
CARDIOPULMONARY BYPASS, |
Received for publication March 5, 1996 Revisions requested May 8, 1996 Revisions received June 6, 1996 Accepted for publication July 18, 1996 Address for reprints: Wulf Dietrich, MD, German Heart Center Munich, Department of Anesthesiology, Lazarettstraße 36, 80636 Munich, Germany.
Abstract
The efficacy of aprotinin to reduce intraoperative bleeding tendency in cardiac operations has been demonstrated in several studies. Aprotinin is a polybasic polypeptide and has antigenic properties. Anaphylactic reactions to aprotinin have been described. The aim of the present study was to evaluate the prevalence of adverse reactions to reexposure to high-dose aprotinin. The clinical outcome of all patients undergoing heart operations in our institution between 1988 and 1995 with at least two exposures to aprotinin was investigated. There were 248 reexposures to aprotinin in 240 patients: 101 adult and 147 pediatric cases. The total aprotinin doses were 4.9 x 106 (interquartile range 2 x 106) KIU (adults) and 1.3 x 106 (interquartile range 1.2 x 106) KIU (pediatric patients). The time between the first and second aprotinin exposures was 344 (interquartile range 1039) days. Seven adverse reactions to aprotinin were found (2.8%). The severity of the reaction ranged from mild (no intervention) to severe (longer-lasting circulatory depression despite vasopressor therapy). All patients survived the event. Patients with an interval less than 6 months since the previous exposure had a statistically higher incidence of adverse reactions than patients with a longer interval (5/111 or 4.5% vs 2/137 or 1.5%, p < 0.05). Two patients reacted to a test dose of 10,000 KIU aprotinin. Pretreatment with antihistaminics was done in 60% of the patients. We recommend the following procedure for reexposure with high-dose aprotinin: (1) delay of the first bolus injection of aprotinin until the surgeon is ready to begin cardiopulmonary bypass, (2) test dose of 10,000 KIU aprotinin in all patients with aprotinin treatment, (3) H1/H2 blockade in known or possible reexposures, and (4) avoidance of reexposure within the first 6 months after the previous exposure to aprotinin. With these precautions a reexposure to aprotinin in patients with a high risk of bleeding is justified, because the benefits of aprotinin treatment outweigh the relative risk of a serious allergic reaction.
This article has been cited by other articles:
|
|
 |
|
  S. Siehr, E. Stuth, J. Tweddell, G. Hoffman, T. Troshynski, D. Jones, M. Mitchell, and N. Ghanayem Hypersensitivity reactions to aprotinin re-exposure in paediatric surgery Eur. J. Cardiothorac. Surg., February 1, 2010; 37(2): 307 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Kober, A. M. Scheule, V. Voth, N. Deschner, E. Schmid, and G. Ziemer Anaphylactic Reaction After Systemic Application of Aprotinin Triggered by Aprotinin-Containing Fibrin Sealant Anesth. Analg., August 1, 2008; 107(2): 406 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schummer, M. Wirsing, and W. Schummer The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock Anesth. Analg., August 1, 2008; 107(2): 620 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy and N. F. Adkinson Jr Anaphylaxis During Cardiac Surgery: Implications for Clinicians Anesth. Analg., February 1, 2008; 106(2): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dietrich, A. Ebell, R. Busley, and A.-L. Boulesteix Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery Ann. Thorac. Surg., October 1, 2007; 84(4): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Mossad, S. Machado, and J. Apostolakis Bleeding following deep hypothermia and circulatory arrest in children. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 34 - 46. [Abstract] [PDF]
|
|
|
|
|
|
S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
W. Beierlein, A. M. Scheule, W. Dietrich, and G. Ziemer Forty Years of Clinical Aprotinin Use: A Review of 124 Hypersensitivity Reactions Ann. Thorac. Surg., February 1, 2005; 79(2): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Hepner and M. C. Castells Anaphylaxis During the Perioperative Period Anesth. Analg., November 1, 2003; 97(5): 1381 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. B. Jaquiss, N. S. Ghanayem, M. C. Zacharisen, K. A. Mussatto, J. S. Tweddell, and S. B. Litwin Safety of Aprotinin Use and Re-Use in Pediatric Cardiothoracic Surgery Circulation, September 24, 2002; 106(12_suppl_1): I-90 - I-94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kyriss, H. Wurst, G. Friedel, R. Jaki, and H. Toomes Reduced blood loss by aprotinin in thoracic surgical operations associated with high risk of bleeding. : A placebo-controlled, randomized phase IV study Eur. J. Cardiothorac. Surg., July 1, 2001; 20(1): 38 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Miyashita, T. Kamibayashi, Y. Ohnishi, J. Kobayashi, and M. Kuro Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid therapy in primary cardiac valve surgery Perfusion, December 1, 2000; 15(6): 507 - 513. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Casati, D. Guzzon, M. Oppizzi, F. Bellotti, A. Franco, C. Gerli, M. Cossolini, G. Torri, G. Calori, S. Benussi, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 520 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Llau and M. L. Garcia-Perez Increased Safety in the Administration of Aprotinin: Need for a Test-Dose Anesth. Analg., March 1, 2000; 90(3): 770 - 771. [Full Text] [PDF]
|
|
|
|
|
|
F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Scheule, W. Beierlein, S. Arnold, F. S. Eckstein, J. M. Albes, and G. Ziemer The Significance of Preformed Aprotinin-Specific Antibodies in Cardiosurgical Patients Anesth. Analg., February 1, 2000; 90(2): 262 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lentschener, P. Cottin, H. Bouaziz, F. J. Mercier, M. Wolf, Y. Aljabi, C. Boyer-Neumann, and D. Benhamou Reduction of Blood Loss and Transfusion Requirement by Aprotinin in Posterior Lumbar Spine Fusion Anesth. Analg., September 1, 1999; 89(3): 590 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Scheule, W. Beierlein, H. P. Wendel, M. J. Jurmann, F. S. Eckstein, and G. Ziemer APROTININ IN FIBRIN TISSUE ADHESIVES INDUCES SPECIFIC ANTIBODY RESPONSE AND INCREASES ANTIBODY RESPONSE OF HIGH-DOSE INTRAVENOUS APPLICATION J. Thorac. Cardiovasc. Surg., August 1, 1999; 118(2): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miyashita, Y. Hayashi, Y. Ohnishi, and M. Kuro Retrospective analysis of effect of low-dose aprotinin priming on allogeneic blood transfusion in repeated cardiac operations Perfusion, May 1, 1999; 14(3): 189 - 194. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Cohen, J. Norberto, R. Cartabuke, and G. Ryu Severe anaphylactic reaction after primary exposure to aprotinin Ann. Thorac. Surg., March 1, 1999; 67(3): 837 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rich The efficacy and safety of aprotinin use in cardiac surgery Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Mannucci Hemostatic Drugs N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253. [Full Text] [PDF]
|
|
|
|
|
|
W. Dietrich Incidence of Hypersensitivity Reactions Ann. Thorac. Surg., June 1, 1998; 65(90060): S60 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Scheule, W. Beierlein, H. P. Wendel, F. S. Eckstein, M. K. Heinemann, and G. Ziemer Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dietrich, K. Schopf, M. Spannagl, M. Jochum, S. L. Braun, and H. Meisner Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations Ann. Thorac. Surg., January 1, 1998; 65(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weipert, H. Meisner, M. Jochum, and W. Dietrich LONG-TERM FOLLOW-UP OF APROTININ-SPECIFIC IMMUNOGLOBULIN G ANTIBODIES AFTER CARDIAC OPERATIONS J. Thorac. Cardiovasc. Surg., October 1, 1997; 114(4): 676 - 678. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
